Quantum Biopharma Debt-to-Equity Ratio Growth & History (QNTM)

Quantum Biopharma's debt-to-equity ratio was 0.20 for fiscal 2025.

View full Quantum Biopharma company overview

Quantum Biopharma annual debt-to-equity ratio history

Quantum Biopharma annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20252025-12-310.200.14+245.91%
20242024-12-310.060.06+1907.07%
20232023-12-310.00−0.00−58.69%
20222022-12-310.010.00+49.83%
20212021-12-310.000.00+35.98%
20202020-12-310.00−0.00−17.54%
20192019-12-310.00

Quantum Biopharma debt-to-equity ratio trends

Over the last five fiscal years, Quantum Biopharma's debt-to-equity ratio increased from 0.00 to 0.20, a change of 0.20. The latest reported quarter, Q2 2026, shows 0.12.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Quantum Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about QNTM yet. Start the conversation.

Write the first post